

Astellas Concludes Agreement with MicroBiopharm Japan on Transfer of Kiyosu Plant Business

Tokyo, October 30, 2015 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “Astellas”) today announced that Astellas and MicroBiopharm Japan Co., Ltd. (Headquarters: Tokyo, President: Masanobu Suzuki, “MBJ”) have concluded an agreement, under which the business of Kiyosu Plant (Kiyosu-shi, Aichi), the manufacturing site, will be transferred to MBJ.

1. Outline of Transfer of Kiyosu Plant Business

(1) Purpose of Transfer

Astellas is engaged in ongoing efforts to create organizations and systems that can flexibly respond to rapidly changing environments and work toward higher quality and efficiency of operations. In the areas of manufacturing and technology as well, Astellas strives to promote the establishment of a stable manufacturing system that would efficiently realize “steady supply of high-quality drugs” in changing environment. As a part of these efforts, Astellas has reached an agreement with MBJ under which the pharmaceutical manufacturing business of Kiyosu Plant will be transferred to MBJ.

The transfer of the Kiyosu Plant business will make Astellas aim to ensure higher quality and efficiency in its manufacturing and technology functions.

The pharmaceutical substances currently manufactured at the Kiyosu Plant are planned to be continuously manufactured there as outsourcing products to MBJ.

MBJ is a CMO that has over 50 years’ experience and technology in fermentation, genetic recombination. Those knowledge and achievements can be applicable to production of the pharmaceutical substances currently manufactured at Kiyosu plant. Taking this opportunity, MBJ will further strengthen and deepen their CMO business in Bio-pharmaceutical fields.

(2) Assets Subject to Transfer

Real estate, movable properties (including facilities and equipment) and pharmaceutical manufacturing business at the Kiyosu Plant

(3) Financial Terms

Financial terms including the value of this transfer are not disclosed.

(4) Schedule for Business Transfer

October 30, 2015 : Execution of an agreement

April 1, 2016 (tentative): Transfer of business

2. Outline of Kiyosu Plant

Location: 156 Nakagawara, Kiyosu-shi, Aichi

Site area: 21,139.18 m²

Building area: 3,270.27 m²

Business description: Manufacturing of pharmaceutical substances

3. Outline of Transferee Company

MicroBiopharm Japan Co., Ltd.

Head office: 1-3-1 Kyobashi, Chuo-ku, Tokyo

Representative: President, Masanobu Suzuki

Capital: 10 million yen (as of July 1, 2015)

Shareholders: Mitsui & Co., Ltd. 80%, Toray Industries, Inc. 20%

Business description: Manufacturing, sales, research and development of pharmaceutical products

Total number of employees: 293 (as of July 1, 2015)

The impact of the execution of this agreement has been accounted in revised Astellas' forecasts for fiscal year ending March 2016, which was announced on October 30, 2015.

About Astellas

Astellas Pharma Inc., based in Tokyo, Japan, is a company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceutical products. We focus on Urology, Oncology, Immunology, Nephrology and Neuroscience as prioritized therapeutic areas while advancing new therapeutic areas and discovery research leveraging new technologies/modalities. We are also creating new value by combining internal capabilities and external expertise in the medical/healthcare business. Astellas is on the forefront of healthcare change to turn innovative science into value for patients. For more information, please visit our website at www.astellas.com/en.

###

Contacts for inquiries or additional information
Astellas Pharma Inc. Corporate Communications TEL: 03-3244-3201 FAX: 03-5201-7473 http://www.astellas.com/en